Edgar Filing: Horizon Pharma plc - Form 4

Horizon Phan Form 4	•										
May 10, 2010	ГЛ								3235-0287		
Check thi if no long subject to Section 1 Form 4 of Form 5 obligation may cont <i>See</i> Instru 1(b).	6. Filed pursuant Section 17(a) of t	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1940							January 31, 2005 average urs per . 0.5		
(Print or Type F	Responses)										
Nohria Virinder Sym			2. Issuer Name and Ticker or Trading Symbol Horizon Pharma plc [HZNP]				5. Relationship of Reporting Person(s) to Issuer				
(M			3. Date of Earliest Transaction(Month/Day/Year)05/06/2016				(Check all applicable) <u>X</u> Director Officer (give title <u>10%</u> Owner below) Other (specify below)				
	(Street) 4. If Amen Filed(Mont						 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 				
DUBLIN, L	24							More than One R			
(City)	(State) (Zip)	Table	e I - Non-D	erivative	Securi	ties Ac	quired, Disposed o	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date 2A. 1 (Month/Day/Year) Exec any (Mon		Date, if TransactionAcquired (A) or Code Disposed of (D) y/Year) (Instr. 8) (Instr. 3, 4 and 5) (A) or)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)				
Ordinary Shares	05/06/2016		М	5,258	А	<u>(1)</u>	5,258	Ι	By Trust		
Ordinary Shares							214,836	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Horizon Pharma plc - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	e 3A. Deemed Execution Date, if any (Month/Day/Year)	Code	5. Number ionof Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	of Derivative Expiration Date Securities (Month/Day/Year) Acquired A) or Disposed of D) Instr. 3, 4,		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Pri Deriv Secu (Instr
				Code V	7 (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Stock Units	<u>(1)</u>	05/06/2016		М	5,258	8 (2)	(2)	Ordinary Shares	5,258	\$

Reporting Owners

Reporting Owner Name / Address			Relationships					
		Director	10% Owner	Officer	Other			
Nohria Virinder C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN, L2 4		Х						
Signatures								
/s/ Paul W. Hoelscher, Attorney-in-Fact	05/10/2016							
**Signature of Reporting Person	Date							
Explanation of Posponso								

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

(2) On May 6, 2015, the reporting person was granted 5,258 restricted stock units, vesting in full on the first anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.